CAJ | 학술논문

以乳酸-羟基乙酸共聚物（PLGA）为材料，采用复乳溶剂挥发法制备无乳链球菌（Streptococcus agalactiae）全菌及超声破碎后的上清微球疫苗。显微镜观察显示随着 PLGA 质量浓度、PVA（聚乙烯醇）质量浓度和外水相体积的增加，上清微球平均粒径均随之增大。最终确定上清微球制备条件为 PLGA 质量浓度25 mg·mL -1、PVA 质量浓度1 mg·mL -1、外水相体积20 mL。全菌微球制备条件与上述的相比，仅 PVA 质量浓度调整为2 mg·mL -1。扫描电镜观察显示全菌和上清微球平均粒径分别为9.4μm 和3.9μm，微球均呈球形。BCA（二喹啉甲酸）法分析显示包封率分别为68.07％和63.49％；载药量分别为5.49×108个·mg -1和3.58％；28 d 体外累积释放量分别为64.2％和82.8％。
이유산-간기을산공취물（PLGA）위재료，채용복유용제휘발법제비무유련구균（Streptococcus agalactiae）전균급초성파쇄후적상청미구역묘。현미경관찰현시수착 PLGA 질량농도、PVA（취을희순）질량농도화외수상체적적증가，상청미구평균립경균수지증대。최종학정상청미구제비조건위 PLGA 질량농도25 mg·mL -1、PVA 질량농도1 mg·mL -1、외수상체적20 mL。전균미구제비조건여상술적상비，부 PVA 질량농도조정위2 mg·mL -1。소묘전경관찰현시전균화상청미구평균립경분별위9.4μm 화3.9μm，미구균정구형。BCA（이규람갑산）법분석현시포봉솔분별위68.07％화63.49％；재약량분별위5.49×108개·mg -1화3.58％；28 d 체외루적석방량분별위64.2％화82.8％。
We prepared polylactic-co-glyconlicacid(PLGA)microparticles containing Streptococcus agalactiae(Group B streptococcus, GBS)whole cell and supernatant after ultrasonication by double emulsion-solvent evaporation method. With increasing PLGA concentra-tion,emulsifier concentration and volume of outer water phase,the average diameter of microparticles containing supernatant increased. We used 25 mg·mL -1 of PLGA,1 mg·mL -1 of emulsifier concentration and 20 mL of outer water phase for preparation of microparticles containing supernatant. The preparation parameters were similar for GBS whole cell microparticles except that the emulsifier concentration was 2 mg·mL -1. The result by scanning electron microscope(SEM)shows that the average diameters of GBS whole cell and supernatant microparticles were 9. 4 μm and 3. 9 μm,respectively,and all the prepared microparticles were spherical in shape. The encapsulation efficiency of GBS whole cell and supernatant microparticles were 68. 07% and 63. 49%,respectively;the drug loading were 5. 49 ×108 ind·mg -1 and 3. 58% ,respectively;the cumulative rate of drug-release over 28 d were 64. 2% and 82. 8% ,respectively.